Recent Study: PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

From: Fast Market Research, Inc.
Published: Fri Mar 27 2015


Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. The CRC market is expected to grow due to the incorporation of five late-stage pipeline agents during the forecast period, including Mologen's MGN1703, Eli Lilly's Cyramza, and Boehringer Ingelheim's nintedanib. Furthermore, GlobalData expects the label extension of Stivarga as a first-line adjuvant treatment for metastatic CRC patients with resected liver metastases. Ultimately, however, GlobalData expects unmet needs to remain unfulfilled by these pipeline agents, and anticipates that novel, innovative approaches, such as those targeting BRAF mutation-positive disease and immune checkpoint inhibitors, will provide the best opportunity for substantial improvement in the prognosis of advanced CRC patients.

Full Report Details at
- http://www.fastmr.com/prod/966202_pharmapoint_colorectal_cancer_global_drug.aspx?afid=301

Highlights

Key Questions Answered

* What are the corporate strategies being used by drug makers?
* How is the disease management evolving? What is the impact for drug manufacturers?
* What opportunities remain after the launch of pipeline agents?
* How large are the metastatic KRAS wild-type and mutation-positive CRC markets for branded agents, and which are growing the fastest?
* What exciting, innovative approaches are being investigated in CRC? Which immunotherapies are of interest to the CRC market?
* What do KOLs think about the latest therapies and drug development strategies?

Key Findings

* By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Colorectal Cancer - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »